Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Specimen Handling 5Magnetic Resonance Spectroscopy 2Biopsy 2pembrolizumab 1dehydroftorafur 1atezolizumab 1Oxaliplatin 1Observation 1Nivolumab 1Naproxen 1Leucovorin 1Ipilimumab 1Fluorouracil 1Endoscopy 1Endoscopic Mucosal Resection 1Diffusion Tensor Imaging 1Colonoscopy 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Colorectal Neoplasms, Hereditary Nonpolyposis × Endoscopic Mucosal Resection × Clear all
NCT05078866 2026-03-03

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
45 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡